scholarly journals New Onset Atrial Fibrillation in Health Profession Student with Newly Diagnosed ADHD: A Case Report on Wellness and Cardiovascular Consequences of Burnout

2020 ◽  
Vol 7 (3) ◽  
Author(s):  
Gao Mary ◽  
Chin Justin ◽  
Nagendiram Gayathri ◽  
Chen Derek ◽  
Rajyaguru Parth ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Case Report ◽  
Health Profession ◽  
Newly Diagnosed ◽  
Health Profession Student ◽  
Profession Student ◽  
Onset Atrial Fibrillation ◽  
New Onset

New-onset atrial fibrillation and warfarin initiation: High risk periods and implications for new antithrombotic drugs

2010 ◽  
Vol 104 (12) ◽  
pp. 1099-1105 ◽  
Author(s):  
Renato D. Lopes ◽  
Elaine M. Hylek ◽  
David A. Garcia
Keyword(s):  
Atrial Fibrillation ◽  
Newly Diagnosed ◽  
Antithrombotic Drugs ◽  
Number Of Patients ◽  
Disproportionate Number ◽  
Randomised Controlled ◽  
Risk For Bleeding ◽  
Onset Atrial Fibrillation ◽  
Anticoagulant Medication ◽  
New Onset

SummaryAtrial fibrillation is a common condition that increases the risk of stroke in many patients. Although warfarin has been shown to reduce the risk of stroke, many patients who might benefit from anticoagulation do not receive this therapy. Fear of bleeding is the most often cited reason. Several new anticoagulant medications are being studied to determine their efficacy and safety relative to warfarin. Unlike earlier trials that established the superiority of warfarin over placebo, recent trials in atrial fibrillation have enrolled a disproportionate number of patients already taking warfarin. This review suggests that the risk of both haemorrhage and stroke are highest when atrial fibrillation is newly diagnosed and during the initiation of anticoagulant medication. Randomised controlled trials designed to evaluate the safety and efficacy of new anti-thrombotic agents should include substantial numbers of patients without prior exposure to anticoagulation since these individuals are at the highest risk for bleeding and thromboembolism.

scholarly journals New-Onset Atrial Fibrillation Detected by Continuous Capnography Monitoring: A Case Report

2020 ◽  
Vol 21 ◽  
Author(s):  
Toby N. Weingarten ◽  
Hiroshi Morimatsu ◽  
Juan Fiorda-Diaz ◽  
Sergio D. Bergese ◽  
Makiko Ariyoshi ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Case Report ◽  
Onset Atrial Fibrillation ◽  
New Onset

scholarly journals Cancer incidence during follow-up in patients with new-onset atrial fibrillation treated with DOACs and its impact on bleeding risk

2021 ◽  
Vol 42 (Supplement_1) ◽  
Author(s):  
F Angeli ◽  
L Bartoli ◽  
M Fabrizio ◽  
L Bergamaschi ◽  
I Magnani ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Risk Assessment ◽  
Oral Anticoagulant ◽  
Metastatic Cancer ◽  
Bleeding Risk ◽  
Newly Diagnosed ◽  
Bleeding Events ◽  
Onset Atrial Fibrillation ◽  
New Onset

Abstract Background Cancer is increasingly recognized as strictly related to atrial fibrillation (AF). In patients with AF, the relationship between cancer and cardioembolic or bleeding risk during oral anticoagulant therapy is unknown. Purpose To assess the bleeding and ischaemic burden of a baseline or newly diagnosed cancer in patients treated with direct oral anticoagulants (DOACs) for non-valvular atrial fibrillation (NVAF). Methods All consecutive patients treated with DOACs were enrolled among those with new-onset atrial fibrillation and indication for oral anticoagulant between January 2017 and March 2019. During follow-up, bleeding events, newly diagnosed primitive or metastatic malignancy and major cardiovascular events (MACE) were evaluated. At baseline, CHA2DS2-VASc, HAS-BLED, ATRIA, and ORBIT scores were used to assess the hemorrhagic and ischaemic risk. Major bleedings (MB) were defined according to the ISTH definition. Anemia was defined as haemoglobin levels below 11 g/dL in women and 12 mg/dL in men. Results 1258 patients constituted the study population and followed for a mean time of 21.6±9.5 months. Overall, 66 patients (5.2%) were affected by malignant neoplasia at baseline, whereas 59 (4.7%) were diagnosed with a malignancy during follow-up. Among baseline characteristics, anemia was associated with cancer at enrolment (43.9% vs 22.5%, p<0.001) but not at follow up (29.3% vs 23.4%, p=0.341). MACEs were not associated with cancer at baseline (5.3% vs 5.2%, p=1.0) and at follow up (5% vs 4.9%, p=1.0). No association was observed between major ischaemic events and cancer at enrolment or follow up (5.3% vs 4.4%, p=0.83 and 4.4% vs 5%, p=0.82). Despite no statistically significant differences in haemorrhagic risk at baseline, the overall bleeding events and MB were associated with newly diagnosed cancer (9.2% vs 3.9%, p=0.001 and 13.8% vs 4.5%, p=0.001, respectively) but not at baseline (5.2% vs 5.5%, p=0.82 and 9.2% vs 5.2%, p=0.162). At multivariate analysis adjusted for age, hypertension and renal function, anemia and a newly diagnosed cancer during follow up remained independent predictors of MB (respectively, HR 1.27, 95% CI 1.52–1.06, p=0.009 and HR 3.53, 95% CI 7.71–1.62, p=0.001). Conclusion Bleeding risk assessment is an ongoing challenge in patients with NVAF on DOACs. During follow-up, newly diagnosed primitive or metastatic cancer is a strong predictor of bleeding regardless of baseline haemorrhagic risk assessment. In contrast, such association is not observed with malignancy at baseline. A proper diagnosis and treatment could therefore decrease cancer-related bleeding risk. On the contrary, our study shows that cancer is not an ischaemic risk modifier, either diagnosed at baseline or follow-up. FUNDunding Acknowledgement Type of funding sources: None.

scholarly journals Peak troponin I level predicts new-onset atrial fibrillation in patients with myocardial infarction

2016 ◽  
Vol 39 (6) ◽  
pp. 213 ◽  
Author(s):  
Regayip Zehir ◽  
Ahmet I Tekkesin ◽  
Nahide Haykir ◽  
Yalcin Velibey ◽  
Edibe B Borklu ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Atrial Fibrillation ◽  
Predictive Value ◽  
Troponin I ◽  
Primary Pci ◽  
Newly Diagnosed ◽  
Index Hospitalization ◽  
Study Population ◽  
Onset Atrial Fibrillation ◽  
New Onset

Purpose: We aimed to assess the predictive value of peak troponin I level for the occurrence of new-onset AF in myocardial infarction. Methods: A total of 1553 patients, who were hospitalized with diagnosis of STEMI and underwent primary PCI, were retrospectively evaluated. New-onset AF was defined as any newly diagnosed AF that occurred during index hospitalization after primary PCI. Results: New-onset AF was observed in 90 patients (5.8% of the study population). Patients who developed AF were older (56.1 vs. 62.6 years, p

P3776Blood pressure variability and incidence of new-onset atrial fibrillation

2019 ◽  
Vol 40 (Supplement_1) ◽  
Author(s):  
E.-K Choi ◽  
S R Lee ◽  
K D Han ◽  
S Oh
Keyword(s):  
Atrial Fibrillation ◽  
High Risk ◽  
High Variability ◽  
Newly Diagnosed ◽  
Risk Patients ◽  
Korean National Health Insurance ◽  
The Mean ◽  
Onset Atrial Fibrillation ◽  
New Onset

Abstract Background Visit-to-visit blood pressure (BP) variability is a known risk factor for stroke, but the association between BP variability and atrial fibrillation (AF) incidence is uncertain. We sought to evaluate the association between BP variability and incident AF. Methods We identified 8,063,922 subjects (mean age 48 years; 59% men) who had ≥3 health checkups provided by the Korean National Health Insurance Corporation between 2004 and 2010. Systolic and diastolic BP variability was defined as variability independence of the mean (VIM). VIM was divided into four groups and high variability of BP was defined as the highest quartile values. The primary end point was new-onset atrial fibrillation. Results During a mean 7 years of follow-up, 140,086 subjects were newly diagnosed with AF (2.53 per 1000 person-years). High variation in BP was associated with an increase in the risk of AF (SBP: hazard ratio [HR], 1.060; 95% confidence interval [CI], 1.044–1.075, DBP: HR, 1.066; 95% CI, 1.050–1.082) compared with subjects with lowest quartile of BP. Among subjects with high variation both in SBP and DBP, the risk of AF was 7.6% higher than subjects without high variation in SBP and DBP. The risk of high BP variation on new-onset AF was more obvious in high-risk patients. The association of high BP variability with AF was being stronger for high-risk subjects who were older (≥65 years), with diabetes, or with CKD compared with subjects who were younger, without diabetes, or without CKD. Conclusions Fluctuation in SBP and DBP was associated with higher incidence of AF, especially in high-risk subjects, independent of traditional AF risk factors.

scholarly journals SARS-COV-2 Presenting as New Onset Atrial Fibrillation: A Case Report

Cureus ◽  
2020 ◽  
Author(s):  
Jason Harhay ◽  
Muniba Khan ◽  
Shalin Shah ◽  
Amit Malhotra
Keyword(s):  
Atrial Fibrillation ◽  
Case Report ◽  
Onset Atrial Fibrillation ◽  
New Onset
Sign in / Sign up

Export Citation Format

Share Document